# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Acute myeloid leukemia

Acute Non Lymphoblastic Leukemia
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 71-80 of 674 results.
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Nov 20, 2019
First Received: Mar 30, 2018
Disease(s): Cancer - Acute Myeloid Leukemia
Intervention(s): Venetoclax, Dinaciclib
Locations: University of Arkansas /ID# 200016, Little Rock, Arkansas, United States
David Geffen School of Medicin /ID# 200015, Los Angeles, California, United States
The University of Chicago /ID# 200017, Chicago, Illinois, United States
Univ Maryland School Medicine /ID# 204015, Baltimore, Maryland, United States
Wake Forest Baptist Medical Center /ID# 200288, Winston-Salem, North Carolina, United States
... and 9 other locations.
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Not yet recruiting
Last Changed: Jan 30, 2020
First Received: Jan 27, 2020
Disease(s): Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Intervention(s): gilteritinib, fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF)
Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients
Status: Recruiting
Last Changed: Nov 29, 2019
First Received: Jul 27, 2016
Disease(s): Acute Myeloid Leukemia
Intervention(s): pembrolizumab, Azacitadine
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland, United States
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Nov 08, 2019
First Received: Aug 10, 2018
Disease(s): Acute Myeloid Leukemia (AML)
Intervention(s): Venetoclax, Gilteritinib
Locations: David Geffen School of Medicin /ID# 200166, Los Angeles, California, United States
UC San Francisco Medical Center-Parnassus /ID# 200205, San Francisco, California, United States
Sylvester Comprehensive Cancer /ID# 200268, Miami, Florida, United States
Northwestern Memorial Hospital /ID# 200230, Chicago, Illinois, United States
Norton Cancer Institute /ID# 200623, Louisville, Kentucky, United States
... and 7 other locations.
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
Status: Recruiting
Last Changed: Dec 06, 2019
First Received: Mar 27, 2015
Disease(s): Acute Myeloid Leukemia
Intervention(s): Crenolanib besylate
Locations: MD Anderson Cancer Center, Houston, Texas, United States
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
Status: Not yet recruiting
Last Changed: Feb 17, 2020
First Received: Dec 20, 2019
Disease(s): Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Intervention(s): Gemtuzumab Ozogamicin, Quality-of-Life Assessment, Questionnaire Administration, Talazoparib, Talazoparib Tosylate
Locations: Roswell Park Cancer Institute, Buffalo, New York, United States
Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.
Status: Recruiting
Last Changed: Oct 25, 2018
First Received: Oct 17, 2017
Disease(s): Acute Myeloid Leukemia
Intervention(s): NGS techniques
Locations: Hospital Reina Sofía, Córdoba, Spain
Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain
Hospital 12 de Octubre, Madrid, Spain
Clínica Universidad de Navarra, Pamplona, Spain
Hospital General Universitario, Salamanca, Spain
... and 3 other locations.
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Oct 17, 2018
First Received: Jul 19, 2017
Disease(s): Acute Myeloid Leukemia
Intervention(s): Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Locations: Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, KunMing, Yunnan, China
A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study
Status: Recruiting
Last Changed: Jul 10, 2018
First Received: May 16, 2017
Disease(s): Acute Myeloid Leukemia
Intervention(s): BL-8040, Atezolizumab
Locations: The University of Texas - Md Anderson Cancer Center - Leukemia Center, Houston, Texas, United States
Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States
Fakultni Nemocnice Brno / University Hospital Brno Interni Hematologicka A Onkologicka Klinika / Internal Hematology and Oncology Clinic, Brno, Czechia
Fakultni Nemocnice Ostrava (Fno) / University Hospital Ostrava Klinika Hematoonkologie / Hematooncology Clinic, Ostrava, Czechia
Fakultni Nemocnice Kralovske Vinohrady Fnkv / University Hospital Kralovske Vinohrady Interní Hematologická Klinika Fnkv / Internal Hematology Clinic, Praha, Czechia
... and 8 other locations.
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Status: Not yet recruiting
Last Changed: Jan 27, 2020
First Received: Dec 18, 2019
Disease(s): Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Intervention(s): Enasidenib, Enasidenib Mesylate